Artificial Intelligence (AI) is rapidly transforming the future of healthcare and biomedical innovation, especially in the field of rare diseases such as Charcot-Marie-Tooth (CMT) disease. Researchers, biotechnology companies, and scientific institutions across the world are increasingly using AI-powered tools to better understand disease biology, accelerate drug discovery, improve clinical research, and support the development of future therapies.

Rare genetic disorders like CMT present unique scientific challenges due to their complex genetics, variable disease progression, and limited availability of large patient datasets. AI-driven technologies are helping address these challenges by enabling faster analysis of biological, clinical, genetic, and movement-related data. These advances are opening new possibilities in precision medicine, disease modeling, biomarker identification, patient monitoring, and therapeutic discovery.

One emerging innovation in this field is the DANCER, an AI-assisted movement analysis tool developed by Dr. Wolfgang Pernice and the CMT Research Foundation in collaboration with Columbia University. DANCER is designed to analyze motor function and movement patterns in individuals affected by CMT using simple 2D smartphone video recordings. Through advanced computer vision and AI-based reconstruction methods, the platform can generate highly detailed 3D whole-body movement models, helping researchers better quantify gait, balance, and functional changes over time. Such approaches may improve disease tracking and support future clinical research methodologies.

AI is also increasingly influencing the future of rare disease drug discovery. Platforms such as VoyageR, developed by ReviR Therapeutics, are exploring AI-enabled approaches for identifying RNA-targeted small-molecule therapies for neurological and genetic disorders, including potential applications related to CMT disease. By combining machine learning, RNA biology, molecular modeling, and structural analysis, these computational systems can rapidly evaluate large chemical libraries and identify molecules with potential therapeutic relevance. Such approaches may help reduce the time and cost traditionally associated with early-stage drug development.

In addition to movement analysis and drug discovery, AI-assisted technologies are being explored globally for:

• • Identification of new therapeutic targets
  • Drug repurposing strategies
  • Biomarker discovery and disease prediction
  • Clinical trial optimization and patient stratification
  • Genetic data interpretation and precision medicine approaches
  • Large-scale patient data analysis through registries and digital health systems

While artificial intelligence does not replace laboratory science, clinical expertise, or patient participation, it has the potential to significantly support and accelerate scientific discovery in rare neurological diseases.

As the global CMT ecosystem continues to evolve, the integration of artificial intelligence, computational biology, patient registries, and collaborative research initiatives may contribute toward improved understanding of CMT disease and future therapeutic opportunities for affected individuals and families worldwide.

Disclaimer

This article is intended solely for educational and awareness purposes. References to DANCER, VoyageR, artificial intelligence platforms, research initiatives, organizations, or emerging technologies are based on publicly available information from their respective institutions and independent scientific sources.

The Charcot Marie Tooth Foundation of India does not claim ownership of the technologies, platforms, trademarks, research projects, or associated intellectual property mentioned in this article unless explicitly stated. References to ongoing research or investigational approaches should not be interpreted as medical advice, endorsement, or guarantees of treatment outcomes.